Owens, C
2020 review of GLP-1 medications The authors of a 2020 publication reviewed all adverse effects associated with certain GLP-1 medications, including semaglutide
And thats whats led to all this public enthusiasm. That enthusiasm is focused on a hugely popular suite of peptides, many of which are not approved for clinical use by health regulators, but are easily accessible, aggressively hyped on social media, and which promise all manner of body optimisations
This means you don't feel as hungry and you eat less
9, 2025), available at: [3] FDA, FDAs Concerns with Unapproved GLP-1 Drugs Used for Weight Loss , (last visited: Sep
The most common symptom is pain and swelling in the big toe, but it can also affect other joints in the foot, ankle, and knee